Literature DB >> 20102305

Inhaled corticosteroids in chronic obstructive pulmonary disease: a review.

Eef D Telenga1, Huib A M Kerstjens, Dirkje S Postma, Nick H Ten Hacken, Maarten van den Berge.   

Abstract

IMPORTANCE OF THE FIELD: Chronic obstructive pulmonary disease (COPD) is a disease characterized by chronic airflow obstruction and a progressive lung function decline. Although widely used, the efficacy of inhaled corticosteroids (ICS) in the treatment of COPD remains a matter of debate. AREAS COVERED IN THIS REVIEW: This article reviews the evidence about the effects of inhaled corticosteroids in the treatment of COPD. WHAT THE READER WILL GAIN: Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the decline of lung function in COPD. Based on these findings, it was concluded that the use of ICS did not influence the natural course of COPD. However, this conclusion has been challenged by two subsequent studies, TORCH and GLUCOLD, which both showed a reduction in lung-function decline over time with the use of ICS. These two studies indicate that ICS might indeed influence the natural course of the disease, at least in a subgroup of COPD patients. TAKE HOME MESSAGE: Further studies are needed to identify which individuals have a favorable short- and long-term response to ICS treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102305     DOI: 10.1517/14656560903510628

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  11 in total

1.  Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease.

Authors:  Stephanie A Christenson; Katrina Steiling; Maarten van den Berge; Kahkeshan Hijazi; Pieter S Hiemstra; Dirkje S Postma; Marc E Lenburg; Avrum Spira; Prescott G Woodruff
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

Review 2.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 3.  Asthma and chronic obstructive pulmonary disease overlap: asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma?

Authors:  Annelies Slats; Christian Taube
Journal:  Ther Adv Respir Dis       Date:  2015-11-22       Impact factor: 4.031

4.  A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices.

Authors:  Thea van den Bosch; Niek G J Leus; Hannah Wapenaar; Alexander Boichenko; Jos Hermans; Rainer Bischoff; Hidde J Haisma; Frank J Dekker
Journal:  Pulm Pharmacol Ther       Date:  2017-03-16       Impact factor: 3.282

5.  Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.

Authors:  Rokhsara Rafii; Timothy E Albertson; Samuel Louie; Andrew L Chan
Journal:  Pulm Med       Date:  2011-04-20

6.  Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity.

Authors:  Maarten van den Berge; Katrina Steiling; Wim Timens; Pieter S Hiemstra; Peter J Sterk; Irene H Heijink; Gang Liu; Yuriy O Alekseyev; Marc E Lenburg; Avrum Spira; Dirkje S Postma
Journal:  Thorax       Date:  2013-08-07       Impact factor: 9.139

7.  GLCCI1 rs37973: a potential genetic predictor of therapeutic response to inhaled corticosteroids in Chinese chronic obstructive pulmonary disease patients.

Authors:  Yuan Lei; Yiping Gao; Jinkun Chen; Miao Li; Xiaomei Wu; Qin Ning; Jianping Zhao; Weining Xiong; Yongjian Xu; Jungang Xie
Journal:  Sci Rep       Date:  2017-02-10       Impact factor: 4.379

8.  HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice.

Authors:  Niek G J Leus; Thea van den Bosch; Petra E van der Wouden; Kim Krist; Maria E Ourailidou; Nikolaos Eleftheriadis; Loes E M Kistemaker; Sophie Bos; Rutger A F Gjaltema; Solomon A Mekonnen; Rainer Bischoff; Reinoud Gosens; Hidde J Haisma; Frank J Dekker
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

9.  Changes in airway histone deacetylase2 in smokers and COPD with inhaled corticosteroids: a randomized controlled trial.

Authors:  Sukhwinder Singh Sohal; David Reid; Amir Soltani; Steven Weston; Hans Konrad Muller; Richard Wood-Baker; Eugene Haydn Walters
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  Budesonide and fluticasone propionate differentially affect the airway epithelial barrier.

Authors:  I H Heijink; M R Jonker; M de Vries; A J M van Oosterhout; E Telenga; N H T Ten Hacken; D S Postma; M van den Berge
Journal:  Respir Res       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.